Until now, Fiocruz had delivered 145 million AstraZeneca vaccines with the active ingredient – Active Pharmacological Input (IFA) – imported from China with a license granted by the European laboratory and university, the ANSA news agency reported.
Now, Anvisa reported that the IFA generated at the Fiocruz Institute of Immunobiological Technology has the same “performance” as the product imported from China.
As of this approval, Fiocruz will be able to begin delivering the first vaccines fully produced in Brazil this month to the National Immunization Program (PNI), run by the Ministry of Health.
According to the television channel CNN Brazil, the Fiocruz Institute of Immunobiological Technology has already manufactured 21 million doses of this vaccine with national supplies.
Vaccination to slow the advance of the pandemic continues to be a politically sensitive issue in Brazil, as President Jair Bolsonaro continues to put up some obstacles or question some aspects of the national campaign, currently the immunization of minors.
However, at the level of governors and public scientific institutions, the country continues to advance in the development, production and delivery of immunizers to expand the protection of society, especially against the new, more contagious variants, such as the current outbreak driven by Omicron.
Source From: Ambito
David William is a talented author who has made a name for himself in the world of writing. He is a professional author who writes on a wide range of topics, from general interest to opinion news. David is currently working as a writer at 24 hours worlds where he brings his unique perspective and in-depth research to his articles, making them both informative and engaging.
